Market Movers rounded up the best reactions from investors and analysts on Eli Lilly . The experts, including Jim Cramer , discussed the drugmaker after it reported second-quarter revenue and earnings Tuesday that beat Wall Street estimates. The company also raised its full-year guidance as quarterly profit soared 85% from the same period last year. Shares of Eli Lilly hit an all-time high during intraday trading, perhaps also getting a boost from a Novo Nordisk trial. The study found Novo Nordisk’s obesity drug Wegovy, which shares some similarities with Lilly’s Mounjaro, cut the risk of heart disease in participants by 20%. Eli Lilly’s stock finished the day about 14.9% higher. LLY is currently held in Cramer’s Charitable Trust portfolio.
